CR20210350A - Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas - Google Patents

Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas

Info

Publication number
CR20210350A
CR20210350A CR20210350A CR20210350A CR20210350A CR 20210350 A CR20210350 A CR 20210350A CR 20210350 A CR20210350 A CR 20210350A CR 20210350 A CR20210350 A CR 20210350A CR 20210350 A CR20210350 A CR 20210350A
Authority
CR
Costa Rica
Prior art keywords
mitochondrial
cscs
therapeutic agent
stem cells
cancer stem
Prior art date
Application number
CR20210350A
Other languages
English (en)
Inventor
Michael P Lisanti
Marco Fiorillo
Federica Sotgia
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of CR20210350A publication Critical patent/CR20210350A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las células madre cancerosas (CSCs) pueden ser erradicadas a través de una estrategia terapéutica novedosa que implica, en algunas modalidades, antibióticos aprobados por la FDA y suplementos dietéticos. El presente planteamiento da por resultado de manera efectiva la erradicación sinérgica de CSCs a través de la inhibición de la biogénesis mitocondrial en CSCs durante el estrés oxidante mitocondrial inducido, sin inhibir las células normales. Las modalidades pueden incluir un agente terapéutico que inhibe la biogénesis mitocondrial y fija como objetivo el ribosoma mitocondrial grande, un agente terapéutico que inhibe la biogénesis mitocondrial y fija como objetivo el ribosoma mitocondrial pequeño y un agente terapéutico que se comporta como un pro-oxidante o induce el estrés oxidante mitocondrial. Las composiciones de acuerdo con el presente planteamiento inhibieron la propagación de CSC por ¿90% en líneas de células MCF7 ER(+) durante estudios preliminares, con una reducción confirmada en el consumo de oxígeno mitocondrial y la producción de ATP. Algunas modalidades incluyen concentraciones sub-antimicrobianas de antibiótico, lo que minimiza en consecuencia los problemas de resistencia a antibióticos. En algunas modalidades, uno o más agentes terapéuticos se conjugan con una señal de fijación de objetivos.
CR20210350A 2018-12-17 2019-12-16 Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas CR20210350A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780488P 2018-12-17 2018-12-17
US201962804411P 2019-02-12 2019-02-12
PCT/US2019/066541 WO2020131696A1 (en) 2018-12-17 2019-12-16 Triple combination therapies for targeting mitochondria and killing cancer stem cells

Publications (1)

Publication Number Publication Date
CR20210350A true CR20210350A (es) 2021-09-27

Family

ID=71102312

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210350A CR20210350A (es) 2018-12-17 2019-12-16 Terapias de combinación triple para fijar como objetivo mitocondrias y aniquilar células madre cancerosas

Country Status (20)

Country Link
US (1) US20220040316A1 (es)
EP (1) EP3897658A4 (es)
JP (1) JP7487205B2 (es)
KR (1) KR20210104829A (es)
CN (1) CN113573715A (es)
AU (1) AU2019403048A1 (es)
BR (1) BR112021011963A2 (es)
CA (1) CA3123838A1 (es)
CL (1) CL2021001614A1 (es)
CO (1) CO2021008999A2 (es)
CR (1) CR20210350A (es)
DO (1) DOP2021000124A (es)
EC (1) ECSP21052747A (es)
IL (1) IL284056A (es)
MX (1) MX2021007345A (es)
PE (1) PE20211551A1 (es)
PH (1) PH12021551434A1 (es)
SG (1) SG11202106516VA (es)
WO (1) WO2020131696A1 (es)
ZA (1) ZA202104255B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115551827A (zh) * 2020-05-13 2022-12-30 卢内拉生物技术有限公司 靶向癌症干细胞和防止转移的9-氨基-多西环素肉豆蔻酰衍生物
WO2023200824A1 (en) * 2022-04-13 2023-10-19 The Wistar Institute Of Anatomy And Biology Delivery system to target gram-negative bacteria

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149776C (da) * 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
JP4573925B2 (ja) * 1998-07-09 2010-11-04 アベンティス・ファーマ・ソシエテ・アノニム 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用
RU2223103C1 (ru) * 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
CN1837229A (zh) * 2005-08-05 2006-09-27 济南思创生物技术有限公司 克拉霉素衍生物及其制备方法和药物应用
US20100173024A1 (en) * 2008-12-01 2010-07-08 LifeSpan Extension, LLC Methods and compositions for altering health, wellbeing, and lifespan
US9180134B2 (en) * 2011-08-18 2015-11-10 Ecole Polytechnique Federale De Lausanne (Epel) Mitochondrial ribosomal proteins as aging regulators
GB201217310D0 (en) * 2012-09-27 2012-11-14 C10 Pharma As Compounds
CN103536530A (zh) * 2013-10-30 2014-01-29 王玉万 盐酸多西环素长效注射剂及制备方法
CU20190096A7 (es) * 2017-03-15 2020-10-20 Lunella Biotech Inc Compuestos derivados de 3-metil-3-hidroxi-4-[(n,n-dimetil)amino]-9-[2-(benciloxi)bencil]-1-oxa-9-azaspiro[5,5]undecano substituidos como inhibidores de la función mitocondrial y composiciones farmacéuticas que los contienen
US11197872B2 (en) * 2017-04-21 2021-12-14 Lunella Biotech, Inc. Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs)
CR20190524A (es) * 2017-05-19 2020-01-10 Lunella Biotech Inc Antimitoscinas: inhibidores específicos de la biogénesis mitocondrial para erradicar células madre cancerosas

Also Published As

Publication number Publication date
AU2019403048A1 (en) 2021-07-08
DOP2021000124A (es) 2021-08-15
KR20210104829A (ko) 2021-08-25
CA3123838A1 (en) 2020-06-25
EP3897658A4 (en) 2022-10-19
WO2020131696A1 (en) 2020-06-25
MX2021007345A (es) 2021-07-15
BR112021011963A2 (pt) 2021-09-08
ZA202104255B (en) 2023-01-25
US20220040316A1 (en) 2022-02-10
JP2022516414A (ja) 2022-02-28
IL284056A (en) 2021-08-31
SG11202106516VA (en) 2021-07-29
ECSP21052747A (es) 2021-08-31
PH12021551434A1 (en) 2021-12-06
CL2021001614A1 (es) 2022-01-14
EP3897658A1 (en) 2021-10-27
JP7487205B2 (ja) 2024-05-20
PE20211551A1 (es) 2021-08-16
CN113573715A (zh) 2021-10-29
CO2021008999A2 (es) 2021-07-30

Similar Documents

Publication Publication Date Title
ZA202202712B (en) Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
PH12021551434A1 (en) Triple combination therapies for targeting mitochondria and killing cancer stem cells
Saeidnia et al. Antioxidants: friends or foe in prevention or treatment of cancer: the debate of the century
Esrefoglu Experimental and clinical evidence of antioxidant therapy in acute pancreatitis
Sharma et al. Effect of ethanolic and aqueous extracts of Bauhinia variegata Linn. on gentamicin-induced nephrotoxicity in rats
PH12020550685A1 (en) Triphenylphosphonium-derivative compounds for eradicating cancer stem cells
Murakami Modulation of protein quality control systems by food phytochemicals
BRPI0513466A (pt) antivìrus natural e composição compreendendo o mesmo
WO2008012666A3 (en) Treatment and prevention mucositis by anthocyanidin derivatives
Maatouk et al. Heated naringin mitigate the genotoxicity effect of Mitomycin C in BALB/c mice through enhancing the antioxidant status
WO2018085816A1 (en) Prooxidant cancer chemo-suppressors and chemo-protectors and methods of use related thereto
Waseem et al. Mitochondria as the target for the modulatory effect of curcumin in oxaliplatin-induced toxicity in isolated rat liver mitochondria
Naqvi et al. DNA degradation by aqueous extract of Aloe vera in the presence of copper ions
BR112015020178A2 (pt) composição com propriedades de inflamação reduzidas para pele biológica e método de redução da inflamação do tecido biológico
WO2009100214A3 (en) Induction of thyroid iodide-handling gene expression in human cancers
Sindhu et al. Carotenoid lutein protects the kidney against cisplatin-induced acute renal failure
Campbell et al. Potential therapeutic agents
Woo et al. Quercetin prevents necrotic cell death induced by co-exposure to benzo (a) pyrene and UVA radiation
AU2016413017B2 (en) Bactericide composition
Verma et al. Mechanism involved in fortification by berberine in CDDP-induced nephrotoxicity
BR112022014650A2 (pt) Derivado de adamantila dissubstituído ou sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para suprimir o crescimento de câncer compreendendo o mesmo como ingrediente ativo
Abd-Rabou et al. 5-fluorouracil synergized with raloxifene and cytosineβ-D-arabinofuranoside to combat colorectal cancers in vitro via controlling lipolysis
Munkhtsetseg et al. Research on the acute toxicity of biologically active compounds derived from Sea buckthorn (Hippophae rhamnoides L.) flakes in vivo
Shim Synthesis and NRF2 activating ability of thiourea and vinyl sulfoxide derivatives
Magalhães et al. Melissa Officinalis L. ethanolic extract interferes with cell cycle and induces apoptosis of non-small cell lung cancer cells